Teva Pharmaceutical Industries Announces Collaboration and Financial Forecasts

Teva Pharmaceutical Industries (TASE: TEVA; NYSE: TEVA) has announced a significant collaboration with Royalty Pharma (Nasdaq: RPRX) aimed at accelerating the development of a novel treatment for vitiligo, a chronic skin condition. Under this agreement, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is currently undergoing a phase 1b trial for vitiligo and a separate phase 2a trial for celiac disease. Royalty Pharma will invest $500 million to support the development costs, which includes $75 million earmarked for research and development to initiate a phase 2b study scheduled for 2026. Should the trials yield positive results, Royalty Pharma has the option to invest an additional $425 million for phase 3 trials. In return, Teva will pay royalties on global sales of the drug if it reaches the market.

The Jerusalem ReportGlobes

Richard Francis, Teva's president and CEO, emphasized the importance of strategic collaborations in fostering innovation, stating, "This agreement with Royalty Pharma enables us to advance our science more efficiently and accelerate our pipeline to deliver meaningful solutions for patients worldwide."

Globes

In conjunction with the collaboration announcement, Teva provided updated financial forecasts during a presentation at the 44th annual J.P. Morgan Healthcare Conference. The company maintains its revenue guidance for 2025 at approximately $16.8-17 billion, with earnings before interest, taxes, depreciation, and amortization (EBITDA) projected to be in the middle of the range at $4.8-5 billion. Earnings per share are expected to be near the upper end of the forecast at $2.55-2.65, while free cash flow is anticipated to be between $1.6-1.9 billion.

Globes

Looking ahead, Teva forecasts that its sales for 2026 will remain comparable to those of 2025 or slightly lower, with low single-digit growth expected in 2027. The company anticipates a mid single-digit compound annual growth rate from 2027 through 2030. Additionally, Teva expects its EBITDA and operating profit to increase compared to 2025, with free cash flow projected to exceed $2.7 billion in 2027 and surpass $3.5 billion by 2030. The company also aims to reduce its net leverage to below two times by 2027.

Globes

Following these announcements, Teva's market capitalization reached $36.7 billion, reflecting a 53% increase in its share price over the past year. On the Tel Aviv Stock Exchange, Teva's share price rose by 0.96%, reaching NIS 105.

Globes

While the announcements have been largely positive, some analysts express caution regarding the long-term viability of Teva's growth projections, particularly in light of the competitive landscape in the pharmaceutical industry and potential regulatory challenges.

The Jerusalem Report

• "Strategic collaborations fuel innovation. This agreement with Royalty Pharma enables us to advance our science more efficiently and accelerate our pipeline to deliver meaningful solutions for patients worldwide." — Richard Francis, President and CEO of Teva Pharmaceutical Industries.

The Jerusalem Report